Payment overview · 2025
General Payments
$2,169.68
5 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel Gaitan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1598865636
Verified facts
What the public records show
CMS Open Payments records show Daniel Gaitan, MD received $2,169.68 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 98.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $2,130.00 | 98.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.38 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.14 | 0.7% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $5.16 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,130.00 | 2 |
| Food and Beverage | $39.68 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $2,130.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $5.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $5.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $5.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 230 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 317 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 77 |
| Jardiance | Empagliflozin | 230 | 44 |
| Ezetimibe | Ezetimibe | 212 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 29 |
| Metformin Hcl | Metformin Hcl | 140 | 40 |
| Losartan Potassium | Losartan Potassium | 136 | 38 |
| Mounjaro | Tirzepatide | 116 | 20 |
| Tramadol Hcl | Tramadol Hcl | 91 | 17 |
| Prednisone | Prednisone | 88 | 56 |
| Gabapentin | Gabapentin | 84 | 21 |
| Lisinopril | Lisinopril | 84 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 14 |
| Eliquis | Apixaban | 77 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 23 |
| Celecoxib | Celecoxib | 67 | 18 |
| Ozempic | Semaglutide | 67 | 16 |
| Repatha Sureclick | Evolocumab | 66 | suppressed |
| Alprazolam | Alprazolam | 65 | 18 |
| Omeprazole | Omeprazole | 62 | 15 |
| Azithromycin | Azithromycin | 61 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 15 |
| Montelukast Sodium | Montelukast Sodium | 61 | 14 |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Allopurinol | Allopurinol | 52 | 15 |
| Rybelsus | Semaglutide | 52 | suppressed |
| Furosemide | Furosemide | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 49 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 47 | 12 |
| Irbesartan | Irbesartan | 46 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Cefdinir | Cefdinir | 41 | 35 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 19 |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Testosterone | Testosterone | 32 | 12 |
| Estradiol | Estradiol | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Atenolol | Atenolol | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,169.68 · 5 records | Novo Nordisk Inc | JARDIANCE, NURTEC ODT, Rybelsus, ZAVZPRET, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error